Clinical Trial Update: A Study of MK0657 in Parkinson's Disease Patients (0657-006) [Phase 1]

View source ↗

Summary

A Phase 1 study of MK0657 in Parkinson's disease patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• MK0657

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Parkinson's Disease | Phase 1 | Status: COMPLETED